



COVID-19 campus closures: [see options for getting or retaining Remote Access](#) to subscribed content

☰ Outline



Get Access

Share

Export

Search ScienceDirect



Advanced

Comparative Biochemistry and Physiology Part C:

Toxicology & Pharmacology

Volume 226, December 2019, 108612

Potential use of 13-mer peptides based on phospholipase and oligoarginine as leishmanicidal agents

Bruno Mendes ^a, José R. Almeida ^b, Nuno Vale ^{c, d}, Paula Gomes ^e, Fernanda R. Gadelha ^f, Saulo L. Da Silva ^{g, h}, Danilo C. Miguel ^a

^a Departamento de Biologia Animal, Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil

^b Universidad Regional Amazónica Ikiam, Km 7 Via Muyuna, Tena, Napo, Ecuador

^c Laboratório de Farmacologia, Departamento de Ciências do Medicamento, Faculdade de Farmácia da Universidade do Porto, Portugal

^d IPATIMUP/Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Portugal

^e LAQV/REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Portugal

^f Departamento de Bioquímica e Biologia Tecidual, Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil

^g Facultad de Ciencias Químicas, Universidad de Cuenca, Cuenca/Azuay, Ecuador.

^h Centro de Innovación de la Salud - EUS/EP, Cuenca/Azuay, Ecuador

Received 19 July 2019, Revised 21 August 2019, Accepted 22 August 2019, Available online 24 August 2019.

[Show less](#)<https://doi.org/10.1016/j.cbpc.2019.108612>[Get rights and content](#)

Highlights


- 13-mer peptides based on phospholipase and oligoarginine sequences are promising leishmanicidal compounds.
- Arginine may confer better antileishmanial activity to cationic peptides than lysine residues.
- 13-mer leishmanicidal peptides interfere with cell membrane permeabilization.
- 13-mer peptides showed low toxicity to mammalian cells.

Abstract

Phospholipase A₂ toxins present in snake venoms interact with biological membranes and serve as structural models for the design of small peptides with anticancer, antibacterial and antiparasitic properties. Oligoarginine peptides are capable of increasing cell membrane permeability (cell penetrating peptides), and for this reason are interesting delivery systems for compounds of pharmacological interest. Inspired by these two families of bioactive molecules, we have synthesized two 13-mer peptides as potential antileishmanial leads gaining insights into structural features useful for the future design of more potent peptides. The peptides included p-Acl, reproducing a natural segment of a Lys49 PLA₂ from *Agkistrodon contortrix laticinctus* snake venom, and its p-AclR7 analogue where all seven lysine residues were replaced by arginines. Both peptides were active against promastigote and amastigote forms of *Leishmania (L.) amazonensis* and *L. (L.) infantum*,

while displaying low cytotoxicity for primary murine macrophages. Spectrofluorimetric studies suggest that permeabilization of the parasite's cell membrane is the probable mechanism of action of these biomolecules. Relevantly, the engineered peptide p-AclR7 was more active in both life stages of *Leishmania* and induced higher rates of ethidium bromide incorporation than its native template p-Acl. Taken together, the results suggest that short peptides based on phospholipase toxins are potential scaffolds for development of antileishmanial candidates. Moreover, specific amino acid substitutions, such those herein employed, may enhance the antiparasitic action of these cationic peptides, encouraging their future biomedical applications.

Graphical abstract



[Download : Download high-res image \(137KB\)](#)

[Download : Download full-size image](#)

[<](#) Previous

Next [>](#)

Keywords

Leishmanicidal activity; Oligoarginine; Peptide; Phospholipase

[Recommended articles](#)[Citing articles \(1\)](#)[View full text](#)

© 2019 Elsevier Inc. All rights reserved.

[About ScienceDirect](#)[Remote access](#)[Shopping cart](#)[Advertise](#)[Contact and support](#)[Terms and conditions](#)[Privacy policy](#)

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the **use of cookies**.

Copyright © 2020 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.

ScienceDirect® is a registered trademark of Elsevier B.V.